• Something wrong with this record ?

Potent spinal parenchymal AAV9-mediated gene delivery by subpial injection in adult rats and pigs

A. Miyanohara, K. Kamizato, S. Juhas, J. Juhasova, M. Navarro, S. Marsala, N. Lukacova, M. Hruska-Plochan, E. Curtis, B. Gabel, J. Ciacci, ET. Ahrens, BK. Kaspar, D. Cleveland, M. Marsala,

. 2016 ; 3 (-) : 16046. [pub] 20160713

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc16027463

Effective in vivo use of adeno-associated virus (AAV)-based vectors to achieve gene-specific silencing or upregulation in the central nervous system has been limited by the inability to provide more than limited deep parenchymal expression in adult animals using delivery routes with the most clinical relevance (intravenous or intrathecal). Here, we demonstrate that the spinal pia membrane represents the primary barrier limiting effective AAV9 penetration into the spinal parenchyma after intrathecal AAV9 delivery. We develop a novel subpial AAV9 delivery technique and AAV9-dextran formulation. We use these in adult rats and pigs to show (i) potent spinal parenchymal transgene expression in white and gray matter including neurons, glial and endothelial cells after single bolus subpial AAV9 delivery; (ii) delivery to almost all apparent descending motor axons throughout the length of the spinal cord after cervical or thoracic subpial AAV9 injection; (iii) potent retrograde transgene expression in brain motor centers (motor cortex and brain stem); and (iv) the relative safety of this approach by defining normal neurological function for up to 6 months after AAV9 delivery. Thus, subpial delivery of AAV9 enables gene-based therapies with a wide range of potential experimental and clinical utilizations in adult animals and human patients.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16027463
003      
CZ-PrNML
005      
20210310114554.0
007      
ta
008      
161005s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/mtm.2016.46 $2 doi
024    7_
$a 10.1038/mtm.2016.46 $2 doi
035    __
$a (PubMed)27462649
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Miyanohara, Atsushi $u Neuroregeneration Laboratory, Department of Anesthesiology, University of California , San Diego, California, USA.
245    10
$a Potent spinal parenchymal AAV9-mediated gene delivery by subpial injection in adult rats and pigs / $c A. Miyanohara, K. Kamizato, S. Juhas, J. Juhasova, M. Navarro, S. Marsala, N. Lukacova, M. Hruska-Plochan, E. Curtis, B. Gabel, J. Ciacci, ET. Ahrens, BK. Kaspar, D. Cleveland, M. Marsala,
520    9_
$a Effective in vivo use of adeno-associated virus (AAV)-based vectors to achieve gene-specific silencing or upregulation in the central nervous system has been limited by the inability to provide more than limited deep parenchymal expression in adult animals using delivery routes with the most clinical relevance (intravenous or intrathecal). Here, we demonstrate that the spinal pia membrane represents the primary barrier limiting effective AAV9 penetration into the spinal parenchyma after intrathecal AAV9 delivery. We develop a novel subpial AAV9 delivery technique and AAV9-dextran formulation. We use these in adult rats and pigs to show (i) potent spinal parenchymal transgene expression in white and gray matter including neurons, glial and endothelial cells after single bolus subpial AAV9 delivery; (ii) delivery to almost all apparent descending motor axons throughout the length of the spinal cord after cervical or thoracic subpial AAV9 injection; (iii) potent retrograde transgene expression in brain motor centers (motor cortex and brain stem); and (iv) the relative safety of this approach by defining normal neurological function for up to 6 months after AAV9 delivery. Thus, subpial delivery of AAV9 enables gene-based therapies with a wide range of potential experimental and clinical utilizations in adult animals and human patients.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kamizato, Kota $u Neuroregeneration Laboratory, Department of Anesthesiology, University of California , San Diego, California, USA.
700    1_
$a Juhas, Stefan $u Institute of Animal Physiology and Genetics, Czech Academy of Sciences , Libechov, Czech Republic.
700    1_
$a Juhasova, Jana $u Institute of Animal Physiology and Genetics, Czech Academy of Sciences , Libechov, Czech Republic.
700    1_
$a Navarro, Michael $u Neuroregeneration Laboratory, Department of Anesthesiology, University of California , San Diego, California, USA.
700    1_
$a Marsala, Silvia $u Neuroregeneration Laboratory, Department of Anesthesiology, University of California , San Diego, California, USA.
700    1_
$a Lukacova, Nada $u Institute of Neurobiology, Slovak Academy of Sciences , Kosice, Slovak Republic.
700    1_
$a Hruska-Plochan, Marian $u Institute of Molecular Life Sciences, University of Zurich , Zurich, Switzerland.
700    1_
$a Curtis, Erik $u Department of Neurosurgery, University of California , San Diego, California, USA.
700    1_
$a Gabel, Brandon $u Department of Neurosurgery, University of California , San Diego, California, USA.
700    1_
$a Ciacci, Joseph $u Department of Neurosurgery, University of California , San Diego, California, USA.
700    1_
$a Ahrens, Eric T. $d 1965- $7 xx0229723 $u Department of Radiology, University of California , San Diego, California, USA.
700    1_
$a Kaspar, Brian K $u Department of Pediatrics, The Ohio State University, The Research Institute at Nationwide Children's Hospital , Columbus, Ohio, USA.
700    1_
$a Cleveland, Don $u Ludwig Institute and Department of Cellular and Molecular Medicine, University of California, San Diego, California, USA; Ludwig Institute and Department of Neurosciences, University of California, San Diego, California, USA.
700    1_
$a Marsala, Martin $u Neuroregeneration Laboratory, Department of Anesthesiology, University of California, San Diego, California, USA; Institute of Neurobiology, Slovak Academy of Sciences, Kosice, Slovak Republic.
773    0_
$w MED00190078 $t Molecular therapy. Methods & clinical development $x 2329-0501 $g Roč. 3, č. - (2016), s. 16046
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27462649 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20161005 $b ABA008
991    __
$a 20210310114551 $b ABA008
999    __
$a ind $b bmc $g 1165777 $s 952093
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 3 $c - $d 16046 $e 20160713 $i 2329-0501 $m Molecular therapy. Methods & clinical development $n Mol Ther Methods Clin Dev $x MED00190078
LZP    __
$a Pubmed-20161005

Find record

Citation metrics

Archiving options